Skip to main content

Table 2 Comparison of values at baseline (BL) and after 6 months (M6) in patients with psoriatic arthritis (PsA) and controls

From: Serum IL-23 significantly decreased in obese patients with psoriatic arthritis six months after a structured weight loss intervention

Analytes

PsA (BL), n = 41

PsA (M6), n = 41

p-value PsA, BL vs M6

Controls (BL), n = 39

Controls (M6), n = 39

p-value controls, BL vs M6

TNF-α, pg/mL

12.92 (9.99–17.20)

12.49 (9.13–17.09)

0.234

11.66 (8.49–13.54)

9.60 (7.84–13.01)

0.003

IL-1β, pg/mLa

12.86 (6.73–19.69)

10.53 (5.02–19.69)

0.231

12.13 (5.30–14.81)

8.61 (5.30–14.28)

0.048

IL-6, pg/mLb

8.72 (6.23–11.18)

7.53 (5.34–10.03)

0.444

7.23 (5.54–9.47)

6.90 (4.92–8.33)

0.005

IL-8, pg/mLc

18.69 (13.55–23.21)

17.68 (13.53–21.65)

0.781

19.28 (13.86–27.32)

16.64 (11.85–19.41)

0.077

IL-12/IL-23 p40d, pg/mL

602.65 (384.93–900.21)

666.57 (333.38–974.17)

0.978

544.11 (333.38–835.83)

466.00 (209.26–729.91)

0.032

IL-13, pg/mLe

906.55 (679.96–1131.63)

885.07 (561.48–1171.12)

0.377

885.07 (650.51–1103.93)

777.97 (551.40–1023.60)

0.053

IL-17, pg/mLf

2.63 (1.58–4.65)

2.43 (0.41–4.48)

0.074

0.86 (0.41–3.35)

0.41 (0.41–2.63)

0.465

IL-23, ng/mLg

0.40 (0.17–0.54)

0.18 (0.10–0.30)

< 0.001

0.54 (0.33–0.71)

0.23 (0.12–0.34)

< 0.001

IFN-γ, pg/mL

61.98 (43.73–76.34)

52.09 (40.50–76.34)

0.134

54.73 (43.83–69.95)

48.80 (40.50–61.98)

0.006

Resistin, ng/mL

12.83 (10.58–15.77)

11.81 (10.05–14.91)

0.341

11.82 (9.22–16.42)

12.45 (9.19–15.04)

0.315

Leptin, ng/mLh

26.28 (14.35–48.73)

9.25 (4.40–16.24)

< 0.001

38.80 (20.47–59.87)

14.04 (10.07–26.92)

< 0.001

HMW adiponectin, µg/mL

3.39 (2.13–5.12)

5.95 (3.78–8.45)

< 0.001

4.26 (2.07–6.45)

5.78 (4.50–7.93)

< 0.001

Tot-adiponectin, µg/mL

4.03 (3.18–6.06)

5.90 (4.04–7.93)

< 0.001

4.16 (3.27–5.11)

5.67 (4.27–6.70)

< 0.001

VAS patients´ global disease activity, mm

34 (19–61)

12 (5–51)

0.001

   

VAS pain, mm

30 (19–63)

20 (5–52)

0.004

   

VAS fatigue, mm

56 (22–67)

25 (8–44)

0.001

   

HAQ, score

0.63 (0.13–1.00)

0.25 (0.00–0.69)

< 0.001

   

DAS28CRP, score

2.9 (2.1–3.7)

2.5 (1.7–3.0)

< 0.001

   

DAPSA, score

15.3 (6.6–29.1)

8.2 (2.8–17.7)

< 0.001

   

BMI, kg/m2

35.2 (34.1–38.1)

29.8 (26.6–31.5)

< 0.001

37.7 (36.7–41.5)

30.4 (27.9–33.2)

< 0.001

CRP, mg/L

4.0 (2.0–8.5)

2.0 (1.0–6.5)

0.041

4.0 (2.0–6.0)

2.0 (1.0–4.0)

< 0.001

  1. Values are median (interquartile range) or n (%)
  2. p-value for comparison between BL and M6 are based on cytokine levels above detection level, present in:
  3. a31 patients with PsA and 28 controls, b41 patients with PsA and 38 controls, c41 patients with PsA and 38 controls, d35 patients with PsA and 29 controls, e40 patients with PsA and 37 controls, f20 patients with PsA and 19 controls, g35 patients with PsA and 38 controls, h40 patients with PsA and 38 controls
  4. BL baseline, BMI body mass index, CRP c-reactive protein, DAPSA disease activity in psoriatic arthritis, DAS28CRP disease activity score, HAQ health assessment questionnaire, HMW high molecular weight, IFN interferon, IL interleukin, M6 month 6 after baseline, TNF tumor necrosis factor, Tot total, VAS visual analogue scale
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us